Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Udelson MD

James E. Udelson MD

Chief, Division of Cardiology; Director, Nuclear Cardiology Laboratory, Tufts Medical Center; Professor, Medicine and Radiology, Tufts University School of Medicine, Boston, Massachusetts

Dr. James Udelson is Chief of the Division of Cardiology as well as Director of Nuclear Cardiology at Tufts Medical Center. He is a Professor of Medicine and Radiology at Tufts University School of Medicine in Boston.

He has been the recipient of several NIH grants for studies of the use of cardiac imaging to better understand the physiology of left ventricular function and to favorably influence clinical decision–making. He has directed and/or participated in numerous clinical trials on heart failure and cardiac imaging, focusing on the role of new therapies and how they affect remodeling, physiology, function, and outcomes.

Dr. Udelson has been involved in editorial capacities for several high-impact journals including Circulation, Circulation: Heart Failure, JAMA Cardiology, the Journal of the American College of Cardiology (JACC), and the Journal of Nuclear Cardiology, among others, and has served on numerous national guideline and appropriate-use criteria writing groups. He has participated in a leadership capacity for professional organizations including the American Society of Nuclear Cardiology, the American College of Cardiology (ACC), and the Heart Failure Society of America. Additionally, he has served on several FDA advisory panels.

Disclosures

  • Advisory boards/trial committees: Bayer; MedTrace; LivaNova; scPharmaceuticals; Cardurion; Imbria; Abiomed; Merck; Cytokinetics; Medtronic; Reprieve Cardiovascular; Alleviant Medical

Recent Contributions to PracticeUpdate:

  1. Speckle Tracking–Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy
  2. Lesion Characteristics and Prognosis of ACS Without Angiographically Significant Coronary Artery Stenosis
  3. Cardiac Imaging in the Evaluation of Cardiovascular Risk
  4. Impact of Multiple Myocardial Scars Detected by CMR in Patients Following STEMI
  5. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure From the PIONEER-HF Trial
  6. An Overview of Cardiorenal Syndrome in Symptomatic Hypertrophic Cardiomyopathy Patients
  7. Identification of Imaging Markers of Coronary Plaque Vulnerability Using Radiomic Analysis of Coronary CTA
  8. ACC 2019: Recommendations From Dr. James Udelson
  9. Clinical and CTA Predictors of Coronary Lesions That Later Progress to Chronic Total Occlusion
  10. Sex Differences in Coronary Artery and Thoracic Aorta Calcification and Association With Cardiovascular Mortality in Heavy Smokers

Most Read This Week

Recently Updated